The Medicines Co. (MDCO) announced that it had achieved the primary and key secondary endpoints for its late-stage study using inclisiran to treat patients with atherosclerotic cardiovascular disease ((ASCVD)) or ASCVD-risk equivalents along with elevated bad cholesterol despite maximum tolerated statins (with or without ezetimibe). Detailed data will be revealed at an upcoming medical conference next week. That is when investors will get a detailed look into data, but for now, the key was to meet the primary endpoint which has been achieved. In addition to this, there are several milestones expected in